ããã«ã¡ã¯ïŒ
ãã¬ãŒããŒè²æè¬åž«ã®äºäžè£åžã§ãã
çãã¬ãããŠãã人ãªããã¿ã³ãã¯è³ªãæãããšããã¢ããã€ã¹ã¯äœåºŠãè³ã«ããããšãããã§ããããããããçèãå¹ççã«æé·ãããã«ã¯ãã¿ã³ãã¯è³ªã ãã§ãªããçåæããµããŒãããæ é€çŽ ããã©ã³ã¹ããæãããšãéèŠã§ãã
ãã®äžã§ããæå€ãªæ³šç®ãéããŠããã®ãããããã³ãªãŒãã§ãããããã³ãªãŒã¯ããã£ãã«ããŒã®å®çªé£æãšããŠæåã§ãããåãªãäœã«ããªãŒéèã§ã¯ãªããçè¥å€§ãåŸæŒãããç§åŠçæ ¹æ ãåŸã ã«è§£æããã€ã€ãããŸãã
æ¬èšäºã§ã¯ããããã³ãªãŒã®æ é€ãšçè¥å€§ã®é¢ä¿ãæŽçããææ°ã®ç ç©¶çµæãèžãŸããŠããã€é£ã¹ãã°æã广çãªã®ããã«ã€ããŠãããããã解説ããŠãããŸãã

ãããã³ãªãŒãšçè¥å€§ã®é¢ä¿
1. çè¥å€§ã®åºæ¬ã¡ã«ããºã
çèã¯ããã¬ãŒãã³ã°ã§æå·ããçç¹ç¶ã修埩ãããéçšã§å€ªã匷ããªããŸãããã®ããã»ã¹ã¯ãçã¿ã³ãã¯åæïŒMPSïŒããšåŒã°ãã以äžã®èŠçŽ ã«ãã£ãŠå€§ããå·Šå³ãããŸãã
- ååãªã¿ã³ãã¯è³ªæåïŒç¹ã«ãã€ã·ã³ïŒ
- mTORçµè·¯ã®æŽ»æ§å
- ãã«ã¢ã³ç°å¢ïŒã€ã³ã¹ãªã³ããã¹ãã¹ããã³ãªã©ïŒ
- ççãé žåã¹ãã¬ã¹ã®ã³ã³ãããŒã«
ããã«ãããã³ãªãŒãé¢ããçç±ã¯ãæé žåäœçšã»ãã«ã¢ã³èª¿æŽã»ä»£è¬ãµããŒãã«åªããŠããç¹ã§ãã
2. ãããã³ãªãŒç¹æã®æ é€çŽ ãšçè¥å€§ãžã®åœ±é¿
â ã¹ã«ãã©ã©ãã¡ã³
ãããã³ãªãŒã«å€ãå«ãŸãããã£ãã±ãã«ã«ã§ã匷åãªæé žåäœçšãæã¡ãŸãã
- éåã«ããé žåã¹ãã¬ã¹ã軜æžããçæå·ããã®ååŸ©ãæ©ãã
- Nrf2çµè·¯ã掻æ§åãã现èã®æé žåã·ã¹ãã ã匷å
- äžéšç ç©¶ã§ã¯ãçèçž®ãæå¶ãã广ã瀺å
â ãã¿ãã³C
- ã³ã©ãŒã²ã³åæãå©ããè ±ãé垯ã®å¥åº·ãç¶æ
- æé žåäœçšã«ãããçåè§£ãæå¶
- éååžåãä¿é²ãããšãã«ã®ãŒä»£è¬ããµããŒã
â ãã°ãã·ãŠã
- çåçž®ã»ãšãã«ã®ãŒç£çã«äžå¯æ¬
- mTORã·ã°ãã«ã掻æ§åããçã¿ã³ãã¯åæãä¿é²
- ç¡ç ã®è³ªãé«ããæé·ãã«ã¢ã³ã®åæ³ã«é¢äž
â é£ç©ç¹ç¶
- è žå ç°å¢ãæŽããçéèèªé žïŒSCFAïŒãç£ç
- SCFAã¯ã€ã³ã¹ãªã³æåæ§ãé«ããçèãžã®æ é€äŸçµŠå¹çãæ¹å
ç ç©¶ããèŠããããã³ãªãŒãšçè¥å€§
è¿å¹Žããããã³ãªãŒããã®æåãçè¥å€§ã«å¯äžããå¯èœæ§ã瀺ãç ç©¶ãå¢ããŠããŠããŸãã
- åç©å®éšã§ã¯ãã¹ã«ãã©ã©ãã¡ã³ãçèçž®ãæããçç·ç¶ãµã€ãºãç¶æãã广ãå ±åã
- ããèšåºç ç©¶ã§ã¯ããããã³ãªãŒæåã«ããçŽæ¥çãªçè¥å€§å¹æã¯éå®çã§ãããé žåã¹ãã¬ã¹è»œæžãå埩ä¿é²ã確èªãããŠããŸãã
- ãã¿ãã³Cããã°ãã·ãŠã æåãå€ã人ã»ã©ãçåãé€èèªäœéã®ç¶æãæå©ãšããç«åŠç ç©¶ãååšã
ã€ãŸãããããã³ãªãŒã¯ãçèã倧ãããã䞻圹ãã§ã¯ãªããçè¥å€§ãæ¯ããè圹ãšããŠéèŠã ãšèããããŸãã
æåã¿ã€ãã³ã°ã¯ãã€ããã¹ãïŒ
1. ãã¬ãŒãã³ã°åïŒãšãã«ã®ãŒä»£è¬ãµããŒãïŒ
- é£ç©ç¹ç¶ãè¡ç³å€ã®æ¥äžæãé²ããå®å®ãããšãã«ã®ãŒäŸçµŠ
- æé žåç©è³ªãçèã®ççã軜æž
2. ãã¬ãŒãã³ã°åŸïŒå埩ãšåæä¿é²ïŒ
- ãã¿ãã³Cãçæå·ããã®å埩ãå©ãã
- ãã°ãã·ãŠã ãçåæã·ã°ãã«ããµããŒã
ð ç¹ã«ãããã㯠ãããã€ã³ãèé¡ãšäžç·ã«æåããããšãéãäºéã®åžåãé«ããçè¥å€§ç°å¢ãæŽããŸãã
3. å°±å¯åïŒæé·ãã«ã¢ã³ãšã®çžä¹å¹æïŒ
- ãã°ãã·ãŠã ã®ãªã©ãã¯ã¹å¹æã§ç¡ç ã®è³ªãåäž
- å€éã®çåæããµããŒã
å®è·µçãªé£ã¹æ¹ã»èª¿çæ³
- é»åã¬ã³ãžå ç±ïŒ1ïœ2åïŒïŒã¹ã«ãã©ã©ãã¡ã³ãå¹çããæå
- ãªãªãŒããªã€ã«ãšäžç·ã«ïŒè溶æ§ãã¿ãã³ã®åžåçUP
- é¶èžèããµãŒã¢ã³ãšçµã¿åããïŒé«ã¿ã³ãã¯ïŒæé žåã®æåŒ·ã»ãã
- ã¹ã ãŒãžãŒïŒæ¶ååžåãæ©ãããã¬åŸã«æé©
ãŸãšã
ãããã³ãªãŒã¯çè¥å€§ãçŽæ¥çã«åŒãèµ·ãã飿ã§ã¯ãããŸããããæé žåã»ãã«ã¢ã³èª¿æŽã»ä»£è¬ãµããŒããšãã芳ç¹ãããçãã¬æå¥œè ã«ãšã£ãŠéåžžã«æçãªé£æã§ãã
ç¹ã«ã
- ãã¬ãŒãã³ã°åŸã«ã¿ã³ãã¯è³ªãšäžç·ã«æåãã
- å°±å¯åã«é©éãåãå
¥ãã
ããšã§ãå埩åãåæå¹çãé«ããå¯èœæ§ããããŸãã
ããããã€ã³ïŒãããã³ãªãŒãã®çµã¿åããã¯ãçèã倧ããããããã®æé©ãªããŒãããŒãšèšããã§ãããã
â»æ¬èšäºã¯ãæ°R25ã«æ²èŒãããå®çžŸãæã¡ããã¬ãŒããŒé€æã¹ã¯ãŒã«ã®è¬åž«ãšããŠã掻åããäºäžè£åžãç£ä¿®ããŠããŸãã
å¥åº·ã»æ é€ã»ãã¬ãŒãã³ã°ã«é¢ããäžè¬çãªæ
å ±æäŸãç®çãšããŠãããå»çäžã®èšºæãæ²»çãç®çãšãããã®ã§ã¯ãããŸããã
äœèª¿ãçç¶ã«äžå®ãããæ¹ã¯ãå¿
ãå»åž«ãå°éã®å»çæ©é¢ã«ãçžè«ãã ããã
åèæç®
- Myzak MC et al. “Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells.” Carcinogenesis. 2004.
- Tranchita E et al. “Dietary magnesium and muscle mass: the evidence from epidemiological and clinical studies.” Nutrients. 2021.
- Gomez-Cabrera MC et al. “Role of vitamin C in muscle recovery and performance.” J Physiol. 2008.
- Tarumoto R et al. “Sulforaphane prevents skeletal muscle atrophy in mice.” Sci Rep. 2018.
- Pedersen BK, Saltin B. “Exercise as medicine – evidence for prescribing exercise as therapy in 26 different chronic diseases.” Scand J Med Sci Sports. 2015.
ã³ã¡ã³ã